PFIZER INC

PFIZER INC has an estimated net worth of $2.4 Billion. This is based on reported shares across multiple companies, which include BioAtla, Inc., Viatris Inc, Cerevel Therapeutics Holdings, Inc., Cortexyme, Inc., IMARA Inc., SpringWorks Therapeutics, Inc., ICU MEDICAL INC/DE, Allogene Therapeutics, Inc., RHYTHM PHARMACEUTICALS, INC., Mirna Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, Flexion Therapeutics Inc, Celladon Corp, Zoetis Inc., ICAGEN INC, ENCYSIVE PHARMACEUTICALS INC, ARQULE INC, FIVE PRIME THERAPEUTICS INC, KING PHARMACEUTICALS INC, Coley Pharmaceutical Group, Inc., pSivida LTD, INSITE VISION INC, Pyxis Oncology, Inc., Oric Pharmaceuticals, Inc., and Zura Bio Ltd.

2008 was PFIZER INC's most active year for acquiring shares with 12 total transactions. PFIZER INC's most active month to acquire stocks was the month of March. 2015 was PFIZER INC's most active year for disposing of shares, totalling 19 transactions. PFIZER INC's most active month to dispose stocks was the month of July. 2011 saw PFIZER INC paying a total of $76,522,164.00 for 12,753,694 shares, this is the most they've acquired in one year. In 2024 PFIZER INC cashed out on 27,349,211 shares for a total of $1,230,714,495.00, their largest year based on trade value.